EGFR and astrocytoma (excluding glioblastoma): Pathology was comprised of glioblastoma, IDH-wildtype, histological grade 4 (n = 214, 65%); oligodendroglioma, IDH-mutant, and 1p/19q-codeleted (n = 32, 10%); astrocytoma, IDH-mutant (n = 50, 15%); and IDH-wildtype, histopathological grade 2 or 3 with molecular alterations either of TERT promoter mutation, EGFR amplification, or 7p+/10q- were considered to be molecular GBM (i.e., Glioblastoma, IDH-wildtype, WHO grade 4) (n = 33, 10%) according to the 2021 WHO Classification of Tumors of the Central Nervous System.